185 related articles for article (PubMed ID: 38618958)
21. High-affinity Rb binding, p53 inhibition, subcellular localization, and transformation by wild-type or tumor-derived shortened Merkel cell polyomavirus large T antigens.
Borchert S; Czech-Sioli M; Neumann F; Schmidt C; Wimmer P; Dobner T; Grundhoff A; Fischer N
J Virol; 2014 Mar; 88(6):3144-60. PubMed ID: 24371076
[TBL] [Abstract][Full Text] [Related]
22. Viral and tumor antigen-specific CD8 T-cell responses in Merkel cell carcinoma.
Samimi M; Benlalam H; Aumond P; Gaboriaud P; Fradin D; Kervarrec T; Florenceau L; Vignard V; Blom A; Touzé A; Gervois N; Labarriere N
Cell Immunol; 2019 Oct; 344():103961. PubMed ID: 31472938
[TBL] [Abstract][Full Text] [Related]
23. T-Cell Responses in Merkel Cell Carcinoma: Implications for Improved Immune Checkpoint Blockade and Other Therapeutic Options.
Gehrcken L; Sauerer T; Schaft N; Dörrie J
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445385
[TBL] [Abstract][Full Text] [Related]
24. Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas.
Vandeven N; Nghiem P
Immunotherapy; 2016 Jul; 8(8):907-21. PubMed ID: 27381685
[TBL] [Abstract][Full Text] [Related]
25. Merkel Cell Carcinoma and Immune Evasion: Merkel Cell Polyomavirus Small T-Antigen‒Induced Surface Changes Can Be Reverted by Therapeutic Intervention.
Schlemeyer T; Ohnezeit D; Virdi S; Körner C; Weißelberg S; Starzonek S; Schumacher U; Grundhoff A; Indenbirken D; Albertini S; Fischer N
J Invest Dermatol; 2022 Nov; 142(11):3071-3081.e13. PubMed ID: 35636504
[TBL] [Abstract][Full Text] [Related]
26. Tumor reactive γδ T cells contribute to a complete response to PD-1 blockade in a Merkel cell carcinoma patient.
Lien SC; Ly D; Yang SYC; Wang BX; Clouthier DL; St Paul M; Gadalla R; Noamani B; Garcia-Batres CR; Boross-Harmer S; Bedard PL; Pugh TJ; Spreafico A; Hirano N; Razak ARA; Ohashi PS
Nat Commun; 2024 Feb; 15(1):1094. PubMed ID: 38321065
[TBL] [Abstract][Full Text] [Related]
27. Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma.
Feldmeyer L; Hudgens CW; Ray-Lyons G; Nagarajan P; Aung PP; Curry JL; Torres-Cabala CA; Mino B; Rodriguez-Canales J; Reuben A; Chen PL; Ko JS; Billings SD; Bassett RL; Wistuba II; Cooper ZA; Prieto VG; Wargo JA; Tetzlaff MT
Clin Cancer Res; 2016 Nov; 22(22):5553-5563. PubMed ID: 27166398
[TBL] [Abstract][Full Text] [Related]
28. Merkel cell polyomavirus oncoproteins induce microRNAs that suppress multiple autophagy genes.
Kumar S; Xie H; Shi H; Gao J; Juhlin CC; Björnhagen V; Höög A; Lee L; Larsson C; Lui WO
Int J Cancer; 2020 Mar; 146(6):1652-1666. PubMed ID: 31180579
[TBL] [Abstract][Full Text] [Related]
29. Antibodies to merkel cell polyomavirus T antigen oncoproteins reflect tumor burden in merkel cell carcinoma patients.
Paulson KG; Carter JJ; Johnson LG; Cahill KW; Iyer JG; Schrama D; Becker JC; Madeleine MM; Nghiem P; Galloway DA
Cancer Res; 2010 Nov; 70(21):8388-97. PubMed ID: 20959478
[TBL] [Abstract][Full Text] [Related]
30. The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy.
Knepper TC; Montesion M; Russell JS; Sokol ES; Frampton GM; Miller VA; Albacker LA; McLeod HL; Eroglu Z; Khushalani NI; Sondak VK; Messina JL; Schell MJ; DeCaprio JA; Tsai KY; Brohl AS
Clin Cancer Res; 2019 Oct; 25(19):5961-5971. PubMed ID: 31399473
[TBL] [Abstract][Full Text] [Related]
31. Tumor cell-intrinsic PD-1 promotes Merkel cell carcinoma growth by activating downstream mTOR-mitochondrial ROS signaling.
Martins C; Rasbach E; Heppt MV; Singh P; Kulcsar Z; Holzgruber J; Chakraborty A; Mucciarone K; Kleffel S; Brandenburg A; Hoetzenecker W; Rahbari NN; DeCaprio JA; Thakuria M; Murphy GF; Ramsey MR; Posch C; Barthel SR; Schatton T
Sci Adv; 2024 Jan; 10(3):eadi2012. PubMed ID: 38241371
[TBL] [Abstract][Full Text] [Related]
32. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.
Nghiem PT; Bhatia S; Lipson EJ; Kudchadkar RR; Miller NJ; Annamalai L; Berry S; Chartash EK; Daud A; Fling SP; Friedlander PA; Kluger HM; Kohrt HE; Lundgren L; Margolin K; Mitchell A; Olencki T; Pardoll DM; Reddy SA; Shantha EM; Sharfman WH; Sharon E; Shemanski LR; Shinohara MM; Sunshine JC; Taube JM; Thompson JA; Townson SM; Yearley JH; Topalian SL; Cheever MA
N Engl J Med; 2016 Jun; 374(26):2542-52. PubMed ID: 27093365
[TBL] [Abstract][Full Text] [Related]
33. Tumor-Infiltrating Merkel Cell Polyomavirus-Specific T Cells Are Diverse and Associated with Improved Patient Survival.
Miller NJ; Church CD; Dong L; Crispin D; Fitzgibbon MP; Lachance K; Jing L; Shinohara M; Gavvovidis I; Willimsky G; McIntosh M; Blankenstein T; Koelle DM; Nghiem P
Cancer Immunol Res; 2017 Feb; 5(2):137-147. PubMed ID: 28093446
[TBL] [Abstract][Full Text] [Related]
34. Viral Status Predicts the Patterns of Genome Methylation and Decitabine Response in Merkel Cell Carcinoma.
Harms PW; Verhaegen ME; Vo JN; Tien JC; Pratt D; Su F; Dhanasekaran SM; Cao X; Mangelberger D; VanGoor J; Choi JE; Ma VT; Dlugosz AA; Chinnaiyan AM
J Invest Dermatol; 2022 Mar; 142(3 Pt A):641-652. PubMed ID: 34474081
[TBL] [Abstract][Full Text] [Related]
35. The biology and treatment of Merkel cell carcinoma: current understanding and research priorities.
Harms PW; Harms KL; Moore PS; DeCaprio JA; Nghiem P; Wong MKK; Brownell I;
Nat Rev Clin Oncol; 2018 Dec; 15(12):763-776. PubMed ID: 30287935
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy for Merkel Cell Carcinoma.
Nagase K; Narisawa Y
Curr Treat Options Oncol; 2018 Sep; 19(11):57. PubMed ID: 30238195
[TBL] [Abstract][Full Text] [Related]
37. Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma.
Spassova I; Ugurel S; Terheyden P; Sucker A; Hassel JC; Ritter C; Kubat L; Habermann D; Farahpour F; Saeedghalati M; Peiffer L; Kumar R; Schrama D; Hoffmann D; Schadendorf D; Becker JC
Clin Cancer Res; 2020 May; 26(9):2257-2267. PubMed ID: 31932494
[TBL] [Abstract][Full Text] [Related]
38. Prognostic Impact of MCPyV and TIL Subtyping in Merkel Cell Carcinoma: Evidence from a Large European Cohort of 95 Patients.
Ricci C; Righi A; Ambrosi F; Gibertoni D; Maletta F; Uccella S; Sessa F; Asioli S; Pellilli M; Maragliano R; La Rosa S; Papotti MG; Asioli S
Endocr Pathol; 2020 Mar; 31(1):21-32. PubMed ID: 31808008
[TBL] [Abstract][Full Text] [Related]
39. PD-1 inhibition in advanced Merkel-cell carcinoma.
Baker H
Lancet Oncol; 2016 Jun; 17(6):e225. PubMed ID: 27132870
[No Abstract] [Full Text] [Related]
40. Multidisciplinary Treatment, Including Locoregional Chemotherapy, for Merkel-Polyomavirus-Positive Merkel Cell Carcinomas: Perspectives for Patients Exhibiting Oncogenic Alternative Δ exon 6-7 TrkAIII Splicing of Neurotrophin Receptor Tropomyosin-Related Kinase A.
Guadagni S; Farina AR; Cappabianca LA; Sebastiano M; Maccarone R; Zelli V; Clementi M; Chiominto A; Bruera G; Ricevuto E; Fiorentini G; Sarti D; Mackay AR
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33153070
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
